Skip to main content
Top
Published in: Dermatology and Therapy 2/2022

Open Access 01-02-2022 | Metastasis | Review

Current Methods and Caveats to Risk Factor Assessment in Cutaneous Squamous Cell Carcinoma (cSCC): A Narrative Review

Authors: Aaron S. Farberg, Alison L. Fitzgerald, Sherrif F. Ibrahim, Stan N. Tolkachjov, Teo Soleymani, Leah M. Douglas, Sarah J. Kurley, Sarah T. Arron

Published in: Dermatology and Therapy | Issue 2/2022

Login to get access

Abstract

Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer, and the number of deaths due to cSCC is estimated to be greater than the number attributed to melanoma. While the majority of cSCC tumors are resectable with clear margins by standard excision practices, some lesions exhibit high-risk factors for which there is evidence of their association with recurrence, metastasis, and disease-specific death. The most commonly used staging systems and guidelines in the USA for cSCC are based on these clinical and pathologic high-risk factors; however, these are limited in their ability to predict adverse events, thus posing a challenge for implementing risk-directed patient management. Since the development of local recurrence and/or metastasis has a profound impact on the survival of patients with cSCC, accurate identification of patients at high risk for poor outcomes is critical, potentially allowing for early and appropriate adjuvant therapy. This review summarizes the current cSCC literature with a focus on how differing clinical assessments within each of the five selected risk factors (perineural invasion, differentiation, depth of invasion, size, and location) can influence the evaluation of patient outcomes, along with summarizing the utility of staging and guidelines, and highlighting the potential for molecular tools to improve upon cSCC risk assessment.
Literature
1.
go back to reference Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166:1069–80.PubMed Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166:1069–80.PubMed
2.
go back to reference Thompson AK, Kelley BF, Prokop LJ, et al. Risk factors for cutaneous squamous cell carcinoma outcomes: a systematic review and meta-analysis. JAMA Dermatol. 2016;152:419–28.PubMedPubMedCentral Thompson AK, Kelley BF, Prokop LJ, et al. Risk factors for cutaneous squamous cell carcinoma outcomes: a systematic review and meta-analysis. JAMA Dermatol. 2016;152:419–28.PubMedPubMedCentral
3.
go back to reference Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013;68:957–66.PubMed Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013;68:957–66.PubMed
4.
go back to reference Clayman GL, Lee JJ, Holsinger FC, et al. Mortality risk from squamous cell skin cancer. J Clin Oncol. 2005;23:759–65.PubMed Clayman GL, Lee JJ, Holsinger FC, et al. Mortality risk from squamous cell skin cancer. J Clin Oncol. 2005;23:759–65.PubMed
6.
go back to reference Bander TS, Nehal KS, Lee EH. Cutaneous squamous cell carcinoma. Dermatol Clin. 2019;37:241–51.PubMed Bander TS, Nehal KS, Lee EH. Cutaneous squamous cell carcinoma. Dermatol Clin. 2019;37:241–51.PubMed
7.
go back to reference Chren M-M, Sahay AP, Bertenthal DS, et al. Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol. 2007;127:1351–7.PubMed Chren M-M, Sahay AP, Bertenthal DS, et al. Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol. 2007;127:1351–7.PubMed
8.
go back to reference Radiotis G, Roberts N, Czajkowska Z, et al. Nonmelanoma skin cancer: disease-specific quality-of-life concerns and distress. Oncol Nurs Forum. 2014;41:57–65.PubMed Radiotis G, Roberts N, Czajkowska Z, et al. Nonmelanoma skin cancer: disease-specific quality-of-life concerns and distress. Oncol Nurs Forum. 2014;41:57–65.PubMed
9.
go back to reference Tripathi R, Knusel KD, Ezaldein HH, Bordeaux JS, Scott JF. Characteristics of patients hospitalized for cutaneous squamous cell carcinoma. Dermatol Surg. 2020;46(6):742–6. Tripathi R, Knusel KD, Ezaldein HH, Bordeaux JS, Scott JF. Characteristics of patients hospitalized for cutaneous squamous cell carcinoma. Dermatol Surg. 2020;46(6):742–6.
10.
go back to reference Wysong A, Newman JG, Covington KR, et al. Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2021;84:361–9.PubMed Wysong A, Newman JG, Covington KR, et al. Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2021;84:361–9.PubMed
11.
go back to reference Puebla-Tornero L, Corchete-Sánchez LA, Conde-Ferreirós A, et al. Performance of Salamanca refinement of the T3-AJCC8 versus the Brigham and Women’s Hospital and Tübingen alternative staging systems for high-risk cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2021;84(4):938–45.PubMed Puebla-Tornero L, Corchete-Sánchez LA, Conde-Ferreirós A, et al. Performance of Salamanca refinement of the T3-AJCC8 versus the Brigham and Women’s Hospital and Tübingen alternative staging systems for high-risk cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2021;84(4):938–45.PubMed
13.
go back to reference Kus KJB, Murad F, Smile TD, et al. Higher metastasis and death rates in cutaneous squamous cell carcinomas with lymphovascular invasion. J Am Acad Dermatol. 2021;S0190–9622(21):02799–807. Kus KJB, Murad F, Smile TD, et al. Higher metastasis and death rates in cutaneous squamous cell carcinomas with lymphovascular invasion. J Am Acad Dermatol. 2021;S0190–9622(21):02799–807.
14.
go back to reference Eigentler TK, Leiter U, Häfner H-M, et al. Survival of patients with cutaneous squamous cell carcinoma: results of a prospective cohort study. J Investig Dermatol. 2017;137:2309–15.PubMed Eigentler TK, Leiter U, Häfner H-M, et al. Survival of patients with cutaneous squamous cell carcinoma: results of a prospective cohort study. J Investig Dermatol. 2017;137:2309–15.PubMed
15.
go back to reference Alam M, Armstrong A, Baum C, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;78:560–78.PubMedCentral Alam M, Armstrong A, Baum C, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;78:560–78.PubMedCentral
16.
go back to reference Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80:208–50.PubMed Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80:208–50.PubMed
17.
go back to reference Batsakis JG. Nerves and neurotropic carcinomas. Ann Otol Rhinol Laryngol. 1985;94:426–7.PubMed Batsakis JG. Nerves and neurotropic carcinomas. Ann Otol Rhinol Laryngol. 1985;94:426–7.PubMed
18.
go back to reference Ross AS, Whalen FM, Elenitsas R, et al. Diameter of involved nerves predicts outcomes in cutaneous squamous cell carcinoma with perineural invasion: an investigator-blinded retrospective cohort study. Dermatol Surg. 2009;35:1859–66.PubMed Ross AS, Whalen FM, Elenitsas R, et al. Diameter of involved nerves predicts outcomes in cutaneous squamous cell carcinoma with perineural invasion: an investigator-blinded retrospective cohort study. Dermatol Surg. 2009;35:1859–66.PubMed
19.
go back to reference Jambusaria-Pahlajani A, Kanetsky PA, Karia PS, et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol. 2013;149:402.PubMed Jambusaria-Pahlajani A, Kanetsky PA, Karia PS, et al. Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol. 2013;149:402.PubMed
20.
go back to reference Garcia-Serra A, Hinerman RW, Mendenhall WM, et al. Carcinoma of the skin with perineural invasion. Head Neck. 2003;25:1027–33.PubMed Garcia-Serra A, Hinerman RW, Mendenhall WM, et al. Carcinoma of the skin with perineural invasion. Head Neck. 2003;25:1027–33.PubMed
21.
go back to reference Schmults CD, Karia PS, Carter JB, et al. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-Institution Cohort Study. JAMA Dermatol. 2013;149:541.PubMed Schmults CD, Karia PS, Carter JB, et al. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-Institution Cohort Study. JAMA Dermatol. 2013;149:541.PubMed
22.
go back to reference Haisma MS, Plaat BEC, Bijl HP, et al. Multivariate analysis of potential risk factors for lymph node metastasis in patients with cutaneous squamous cell carcinoma of the head and neck. J Am Acad Dermatol. 2016;75:722–30.PubMed Haisma MS, Plaat BEC, Bijl HP, et al. Multivariate analysis of potential risk factors for lymph node metastasis in patients with cutaneous squamous cell carcinoma of the head and neck. J Am Acad Dermatol. 2016;75:722–30.PubMed
23.
go back to reference Peat B, Insull P, Ayers R. Risk stratification for metastasis from cutaneous squamous cell carcinoma of the head and neck. ANZ J Surg. 2012;82:230–3.PubMed Peat B, Insull P, Ayers R. Risk stratification for metastasis from cutaneous squamous cell carcinoma of the head and neck. ANZ J Surg. 2012;82:230–3.PubMed
24.
go back to reference Upton M, Kita A, Scapa J, St John M. Prognostic value of tumor staging: predicting nodal metastases in cutaneous squamous cell carcinoma. Laryngoscope. 2021;131(1):E170–5. Upton M, Kita A, Scapa J, St John M. Prognostic value of tumor staging: predicting nodal metastases in cutaneous squamous cell carcinoma. Laryngoscope. 2021;131(1):E170–5.
25.
go back to reference Brougham N, Dennett E, Cameron R, et al. The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors. J Surg Oncol. 2012;106:811–5.PubMed Brougham N, Dennett E, Cameron R, et al. The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors. J Surg Oncol. 2012;106:811–5.PubMed
26.
go back to reference Kyrgidis A, Tzellos T, Kechagias N, et al. Cutaneous squamous cell carcinoma (SCC) of the head and neck: risk factors of overall and recurrence-free survival. Eur J Cancer. 2010;46:1563–72.PubMed Kyrgidis A, Tzellos T, Kechagias N, et al. Cutaneous squamous cell carcinoma (SCC) of the head and neck: risk factors of overall and recurrence-free survival. Eur J Cancer. 2010;46:1563–72.PubMed
27.
go back to reference Conde-Ferreirós A, Corchete LA, Jaka A, et al. Patterns of incidental perineural invasion and prognosis in cutaneous squamous cell carcinoma: A multicenter, retrospective cohort study. J Am Acad Dermatol. 2021;84(6):1708–12.PubMed Conde-Ferreirós A, Corchete LA, Jaka A, et al. Patterns of incidental perineural invasion and prognosis in cutaneous squamous cell carcinoma: A multicenter, retrospective cohort study. J Am Acad Dermatol. 2021;84(6):1708–12.PubMed
28.
go back to reference Carter JB, Johnson MM, Chua TL, et al. Outcomes of primary cutaneous squamous cell carcinoma with perineural invasion: an 11-year cohort study. JAMA Dermatol. 2013;149:35.PubMed Carter JB, Johnson MM, Chua TL, et al. Outcomes of primary cutaneous squamous cell carcinoma with perineural invasion: an 11-year cohort study. JAMA Dermatol. 2013;149:35.PubMed
29.
go back to reference Karia PS, Jambusaria-Pahlajani A, Harrington DP, et al. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women’s Hospital Tumor Staging for Cutaneous Squamous Cell Carcinoma. J Clin Oncol. 2014;32:327–34.PubMed Karia PS, Jambusaria-Pahlajani A, Harrington DP, et al. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women’s Hospital Tumor Staging for Cutaneous Squamous Cell Carcinoma. J Clin Oncol. 2014;32:327–34.PubMed
30.
go back to reference Khan K, Mykula R, Kerstein R, et al. A 5-year follow-up study of 633 cutaneous SCC excisions: rates of local recurrence and lymph node metastasis. J Plast Reconstr Aesthet Surg. 2018;71:1153–8.PubMed Khan K, Mykula R, Kerstein R, et al. A 5-year follow-up study of 633 cutaneous SCC excisions: rates of local recurrence and lymph node metastasis. J Plast Reconstr Aesthet Surg. 2018;71:1153–8.PubMed
31.
go back to reference Trosman S, Zhu A, Nicolli EA, Leibowitz JM, Sargi ZB. High-risk cutaneous squamous cell cancer of the head and neck: Risk factors for recurrence and impact of adjuvant treatment. Laryngoscope. 2021;131(1):E136–43.PubMed Trosman S, Zhu A, Nicolli EA, Leibowitz JM, Sargi ZB. High-risk cutaneous squamous cell cancer of the head and neck: Risk factors for recurrence and impact of adjuvant treatment. Laryngoscope. 2021;131(1):E136–43.PubMed
32.
go back to reference Cañueto J, Jaka A, Corchete LA, et al. Postoperative radiotherapy provides better local control and long-term outcome in selective cases of cutaneous squamous cell carcinoma with perineural invasion. J Eur Acad Dermatol Venereol. 2020;34(5):1080–91.PubMed Cañueto J, Jaka A, Corchete LA, et al. Postoperative radiotherapy provides better local control and long-term outcome in selective cases of cutaneous squamous cell carcinoma with perineural invasion. J Eur Acad Dermatol Venereol. 2020;34(5):1080–91.PubMed
33.
go back to reference Jambusaria-Pahlajani A, Miller CJ, Quon H, et al. Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes. Dermatol Surg. 2009;35:574–84.PubMed Jambusaria-Pahlajani A, Miller CJ, Quon H, et al. Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes. Dermatol Surg. 2009;35:574–84.PubMed
34.
go back to reference Ruiz ES, Koyfman SA, Que SKT, et al. Evaluation of the utility of localized adjuvant radiation for node-negative primary cutaneous squamous cell carcinoma with clear histologic margins. J Am Acad Dermatol. 2020;82:420–9.PubMed Ruiz ES, Koyfman SA, Que SKT, et al. Evaluation of the utility of localized adjuvant radiation for node-negative primary cutaneous squamous cell carcinoma with clear histologic margins. J Am Acad Dermatol. 2020;82:420–9.PubMed
35.
go back to reference Tschetter AJ, Campoli MR, Zitelli JA, et al. Long-term clinical outcomes of patients with invasive cutaneous squamous cell carcinoma treated with Mohs micrographic surgery: a 5-year, multicenter, prospective cohort study. J Am Acad Dermatol. 2020;82:139–48.PubMed Tschetter AJ, Campoli MR, Zitelli JA, et al. Long-term clinical outcomes of patients with invasive cutaneous squamous cell carcinoma treated with Mohs micrographic surgery: a 5-year, multicenter, prospective cohort study. J Am Acad Dermatol. 2020;82:139–48.PubMed
36.
go back to reference Marrazzo G, Zitelli JA, Brodland D. Clinical outcomes in high-risk squamous cell carcinoma patients treated with Mohs micrographic surgery alone. J Am Acad Dermatol. 2019;80:633–8.PubMed Marrazzo G, Zitelli JA, Brodland D. Clinical outcomes in high-risk squamous cell carcinoma patients treated with Mohs micrographic surgery alone. J Am Acad Dermatol. 2019;80:633–8.PubMed
37.
go back to reference Roozeboom M, Lohman B, Westers-Attema A, et al. Clinical and histological prognostic factors for local recurrence and metastasis of cutaneous squamous cell carcinoma: analysis of a defined population. Acta Derm Venerol. 2013;93:417–21.PubMed Roozeboom M, Lohman B, Westers-Attema A, et al. Clinical and histological prognostic factors for local recurrence and metastasis of cutaneous squamous cell carcinoma: analysis of a defined population. Acta Derm Venerol. 2013;93:417–21.PubMed
39.
go back to reference Obermeier K, Troltzsch M, Ehrenfeld M, et al. Risk factors for lymph node metastases of facial cutaneous squamous cell carcinoma. J Craniomaxillofac Surg. 2017;45:1138–42.PubMed Obermeier K, Troltzsch M, Ehrenfeld M, et al. Risk factors for lymph node metastases of facial cutaneous squamous cell carcinoma. J Craniomaxillofac Surg. 2017;45:1138–42.PubMed
40.
go back to reference Mourouzis C, Boynton A, Grant J, et al. Cutaneous head and neck SCCs and risk of nodal metastasis—UK experience. J Cranio-Maxillofac Surg. 2009;37:443–7. Mourouzis C, Boynton A, Grant J, et al. Cutaneous head and neck SCCs and risk of nodal metastasis—UK experience. J Cranio-Maxillofac Surg. 2009;37:443–7.
41.
go back to reference Szewczyk M, Pazdrowski J, Golusiński P, et al. Analysis of selected risk factors for nodal metastases in head and neck cutaneous squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2015;272:3007–12.PubMed Szewczyk M, Pazdrowski J, Golusiński P, et al. Analysis of selected risk factors for nodal metastases in head and neck cutaneous squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2015;272:3007–12.PubMed
42.
go back to reference Manyam BV, Garsa AA, Chin R-I, et al. A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck. Cancer. 2017;123:2054–60.PubMed Manyam BV, Garsa AA, Chin R-I, et al. A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck. Cancer. 2017;123:2054–60.PubMed
43.
go back to reference Scottish Intercollegiate Guidelines Network, Healthcare Improvement Scotland. Management of primary cutaneous squamous cell carcinoma: a national clinical guideline. 2014. Edinburgh, Scotland: Scottish Intercollegiate Guidelines Network (SIGN). http://resource.nlm.nih.gov/101671126. Scottish Intercollegiate Guidelines Network, Healthcare Improvement Scotland. Management of primary cutaneous squamous cell carcinoma: a national clinical guideline. 2014. Edinburgh, Scotland: Scottish Intercollegiate Guidelines Network (SIGN). http://​resource.​nlm.​nih.​gov/​101671126.
44.
go back to reference Ch’ng S, Clark JR, Brunner M, et al. Relevance of the primary lesion in the prognosis of metastatic cutaneous squamous cell carcinoma. Head Neck. 2013;35:190–4.PubMed Ch’ng S, Clark JR, Brunner M, et al. Relevance of the primary lesion in the prognosis of metastatic cutaneous squamous cell carcinoma. Head Neck. 2013;35:190–4.PubMed
45.
go back to reference Brinkman J, Hajder E, van der Holt B, et al. The effect of differentiation grade of cutaneous squamous cell carcinoma on excision margins, local recurrence, metastasis and patient survival. Ann Plast Surg. 2015;75:323–6.PubMed Brinkman J, Hajder E, van der Holt B, et al. The effect of differentiation grade of cutaneous squamous cell carcinoma on excision margins, local recurrence, metastasis and patient survival. Ann Plast Surg. 2015;75:323–6.PubMed
47.
go back to reference Pastuszek A, Hanson M, Grigg R. Squamous cell carcinoma of the lip: depth of invasion, local recurrence and regional metastases Experience of a rural multidisciplinary head and neck unit. J Laryngol Otol. 2016;130(Suppl 1):S32-37.PubMed Pastuszek A, Hanson M, Grigg R. Squamous cell carcinoma of the lip: depth of invasion, local recurrence and regional metastases Experience of a rural multidisciplinary head and neck unit. J Laryngol Otol. 2016;130(Suppl 1):S32-37.PubMed
48.
go back to reference Prezzano JC, Scott GA, Lambert Smith F, et al. Concordance of Squamous cell carcinoma histologic grading among dermatopathologists and Mohs surgeons. Dermatol Surg. 2021;47:1433–7.PubMed Prezzano JC, Scott GA, Lambert Smith F, et al. Concordance of Squamous cell carcinoma histologic grading among dermatopathologists and Mohs surgeons. Dermatol Surg. 2021;47:1433–7.PubMed
49.
go back to reference Schmults CD, editor. High-risk cutaneous squamous cell carcinoma: a practical guide for patient management. Berlin: Springer; 2016. Schmults CD, editor. High-risk cutaneous squamous cell carcinoma: a practical guide for patient management. Berlin: Springer; 2016.
50.
go back to reference Bourlidou E, Vahtsevanos K, Kyrgidis A, et al. Risk factors for local recurrence of basal cell carcinoma and cutaneous squamous cell carcinoma of the middle third of the face: a 15-year retrospective analysis based on a single centre. Eur J Dermatol. 2019;29:490–9.PubMed Bourlidou E, Vahtsevanos K, Kyrgidis A, et al. Risk factors for local recurrence of basal cell carcinoma and cutaneous squamous cell carcinoma of the middle third of the face: a 15-year retrospective analysis based on a single centre. Eur J Dermatol. 2019;29:490–9.PubMed
51.
go back to reference Metchnikoff C, Mully T, Singer JP, et al. The 7th edition AJCC staging system for cutaneous squamous cell carcinoma accurately predicts risk of recurrence for heart and lung transplant recipients. J Am Acad Dermatol. 2012;67:829–35.PubMedPubMedCentral Metchnikoff C, Mully T, Singer JP, et al. The 7th edition AJCC staging system for cutaneous squamous cell carcinoma accurately predicts risk of recurrence for heart and lung transplant recipients. J Am Acad Dermatol. 2012;67:829–35.PubMedPubMedCentral
52.
go back to reference Breuninger H, Brantsch K, Eigentler T, et al. Comparison and evaluation of the current staging of cutaneous carcinomas. J Dtsch Dermatol Ges. 2012;10:579–86.PubMed Breuninger H, Brantsch K, Eigentler T, et al. Comparison and evaluation of the current staging of cutaneous carcinomas. J Dtsch Dermatol Ges. 2012;10:579–86.PubMed
53.
go back to reference Wang DM, Kraft S, Rohani P, et al. Association of nodal metastasis and mortality with vermilion vs cutaneous lip location in cutaneous squamous cell carcinoma of the lip. JAMA Dermatol. 2018;154:701–7.PubMedPubMedCentral Wang DM, Kraft S, Rohani P, et al. Association of nodal metastasis and mortality with vermilion vs cutaneous lip location in cutaneous squamous cell carcinoma of the lip. JAMA Dermatol. 2018;154:701–7.PubMedPubMedCentral
54.
go back to reference Feinstein S, Higgins S, Ahadiat O, et al. A retrospective cohort study of cutaneous squamous cell carcinoma with lymph node metastasis: risk factors and clinical course. Dermatol Surg. 2019;45:772–81.PubMed Feinstein S, Higgins S, Ahadiat O, et al. A retrospective cohort study of cutaneous squamous cell carcinoma with lymph node metastasis: risk factors and clinical course. Dermatol Surg. 2019;45:772–81.PubMed
56.
go back to reference Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann Surg Oncol. 2010;17:1471–4.PubMed Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann Surg Oncol. 2010;17:1471–4.PubMed
57.
go back to reference Miller S. Staging cutaneous squamous cell carcinoma. JAMA Dermatol. 2013;149:472–4.PubMed Miller S. Staging cutaneous squamous cell carcinoma. JAMA Dermatol. 2013;149:472–4.PubMed
58.
go back to reference Roscher I, Falk RS, Vos L, et al. Notice of retraction and replacement: Roscher et al. validating 4 staging systems for cutaneous squamous cell carcinoma using population-based data: a nested case-control study. JAMA Dermatol. 2018;154(4):428–34PubMedPubMedCentral Roscher I, Falk RS, Vos L, et al. Notice of retraction and replacement: Roscher et al. validating 4 staging systems for cutaneous squamous cell carcinoma using population-based data: a nested case-control study. JAMA Dermatol. 2018;154(4):428–34PubMedPubMedCentral
59.
go back to reference Warner CL, Cockerell CJ. The new seventh edition American Joint Committee on Cancer staging of cutaneous non-melanoma skin cancer: a critical review. Am J Clin Dermatol. 2011;12:147–54.PubMed Warner CL, Cockerell CJ. The new seventh edition American Joint Committee on Cancer staging of cutaneous non-melanoma skin cancer: a critical review. Am J Clin Dermatol. 2011;12:147–54.PubMed
60.
go back to reference Cañueto J, Burguillo J, Moyano-Bueno D, et al. Comparing the eighth and the seventh editions of the American Joint Committee on Cancer staging system and the Brigham and Women’s Hospital alternative staging system for cutaneous squamous cell carcinoma: implications for clinical practice. J Am Acad Dermatol. 2019;80:106-113.e2.PubMed Cañueto J, Burguillo J, Moyano-Bueno D, et al. Comparing the eighth and the seventh editions of the American Joint Committee on Cancer staging system and the Brigham and Women’s Hospital alternative staging system for cutaneous squamous cell carcinoma: implications for clinical practice. J Am Acad Dermatol. 2019;80:106-113.e2.PubMed
61.
go back to reference Ruiz ES, Karia PS, Besaw R, et al. Performance of the American Joint Committee on Cancer Staging Manual, 8th Edition vs the Brigham and Women’s Hospital Tumor Classification System for Cutaneous Squamous Cell Carcinoma. JAMA Dermatol. 2019;155:819.PubMedPubMedCentral Ruiz ES, Karia PS, Besaw R, et al. Performance of the American Joint Committee on Cancer Staging Manual, 8th Edition vs the Brigham and Women’s Hospital Tumor Classification System for Cutaneous Squamous Cell Carcinoma. JAMA Dermatol. 2019;155:819.PubMedPubMedCentral
62.
go back to reference Karia PS, Morgan FC, Califano JA, et al. Comparison of tumor classifications for cutaneous squamous cell carcinoma of the head and neck in the 7th vs 8th edition of the AJCC Cancer Staging Manual. JAMA Dermatol. 2018;154:175.PubMed Karia PS, Morgan FC, Califano JA, et al. Comparison of tumor classifications for cutaneous squamous cell carcinoma of the head and neck in the 7th vs 8th edition of the AJCC Cancer Staging Manual. JAMA Dermatol. 2018;154:175.PubMed
63.
go back to reference Conde-Ferreirós A, Corchete LA, Puebla-Tornero L, et al. Definition of prognostic subgroups in the T3 stage of the eighth edition of the American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: tentative T3 stage subclassification. J Am Acad Dermatol. 2021;85(5):1168–77. Conde-Ferreirós A, Corchete LA, Puebla-Tornero L, et al. Definition of prognostic subgroups in the T3 stage of the eighth edition of the American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: tentative T3 stage subclassification. J Am Acad Dermatol. 2021;85(5):1168–77.
64.
go back to reference Amin MB, Edge S, Greene F, et al. editors. AJCC cancer staging manual. 8th ed. New York: Springer International Publishing; 2017. Amin MB, Edge S, Greene F, et al. editors. AJCC cancer staging manual. 8th ed. New York: Springer International Publishing; 2017.
65.
go back to reference Jambusaria-Pahlajani A, Hess SD, Katz KA, et al. Uncertainty in the perioperative management of high-risk cutaneous squamous cell carcinoma among Mohs surgeons. Arch Dermatol. 2010;146:1225–31.PubMed Jambusaria-Pahlajani A, Hess SD, Katz KA, et al. Uncertainty in the perioperative management of high-risk cutaneous squamous cell carcinoma among Mohs surgeons. Arch Dermatol. 2010;146:1225–31.PubMed
66.
go back to reference Patel VA, McCullum C, Sparks AD, Schmults CD, Arron ST, Jambusaria-Pahlajani A. Cutaneous squamous cell carcinoma staging may influence management in users: A survey study. Cancer Med. 2022;11(1):94–103.PubMed Patel VA, McCullum C, Sparks AD, Schmults CD, Arron ST, Jambusaria-Pahlajani A. Cutaneous squamous cell carcinoma staging may influence management in users: A survey study. Cancer Med. 2022;11(1):94–103.PubMed
67.
go back to reference Litchman GH, Fitzgerald AL, Kurley SJ, et al. Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma. Curr Med Res Opin. 2020;4:1–6. Litchman GH, Fitzgerald AL, Kurley SJ, et al. Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma. Curr Med Res Opin. 2020;4:1–6.
68.
go back to reference Teplitz R, Giselle P, Litchman GH, et al. Impact of gene expression profile testing on the management of squamous cell carcinoma by dermatologists. J Drugs Dermatol. 2019;18:980–4. Teplitz R, Giselle P, Litchman GH, et al. Impact of gene expression profile testing on the management of squamous cell carcinoma by dermatologists. J Drugs Dermatol. 2019;18:980–4.
69.
go back to reference Inman GJ, Wang J, Nagano A, et al. The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature. Nat Commun. 2018;9:3667.PubMedPubMedCentral Inman GJ, Wang J, Nagano A, et al. The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature. Nat Commun. 2018;9:3667.PubMedPubMedCentral
70.
go back to reference Warren TA, Broit N, Simmons JL, et al. Expression profiling of cutaneous squamous cell carcinoma with perineural invasion implicates the p53 pathway in the process. Sci Rep. 2016;6:283. Warren TA, Broit N, Simmons JL, et al. Expression profiling of cutaneous squamous cell carcinoma with perineural invasion implicates the p53 pathway in the process. Sci Rep. 2016;6:283.
71.
go back to reference Wei W, Chen Y, Xu J, et al. Identification of biomarker for cutaneous squamous cell carcinoma using microarray data analysis. J Cancer. 2018;9:400–6.PubMedPubMedCentral Wei W, Chen Y, Xu J, et al. Identification of biomarker for cutaneous squamous cell carcinoma using microarray data analysis. J Cancer. 2018;9:400–6.PubMedPubMedCentral
72.
go back to reference Compton C. Precision medicine core: progress in prognostication-populations to patients. Ann Surg Oncol. 2018;25:349–50.PubMed Compton C. Precision medicine core: progress in prognostication-populations to patients. Ann Surg Oncol. 2018;25:349–50.PubMed
73.
go back to reference Plasseraud KM, Cook RW, Tsai T, et al. Clinical performance and management outcomes with the DecisionDx-UM gene expression profile test in a prospective multicenter study. J Oncol. 2016;2016:5325762. https://doi.org/10.1155/2016/5325762. Plasseraud KM, Cook RW, Tsai T, et al. Clinical performance and management outcomes with the DecisionDx-UM gene expression profile test in a prospective multicenter study. J Oncol. 2016;2016:5325762. https://​doi.​org/​10.​1155/​2016/​5325762.​
74.
go back to reference Aaberg TM, Cook RW, Oelschlager K, et al. Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses. Clin Ophthalmol. 2014;8:2449–60.PubMedPubMedCentral Aaberg TM, Cook RW, Oelschlager K, et al. Current clinical practice: differential management of uveal melanoma in the era of molecular tumor analyses. Clin Ophthalmol. 2014;8:2449–60.PubMedPubMedCentral
75.
go back to reference Berger AC, Davidson RS, Poitras JK, et al. Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients. Curr Med Res Opin. 2016;32:1599–604.PubMed Berger AC, Davidson RS, Poitras JK, et al. Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients. Curr Med Res Opin. 2016;32:1599–604.PubMed
76.
go back to reference Farberg AS, Glazer AM, Winkelmann RR, et al. Assessing genetic expression profiles in melanoma prognosis. Dermatol Clinics. 2017;35:545–50. Farberg AS, Glazer AM, Winkelmann RR, et al. Assessing genetic expression profiles in melanoma prognosis. Dermatol Clinics. 2017;35:545–50.
77.
go back to reference Dillon LD, Gadzia JE, Davidson RS, et al. Prospective, multicenter clinical impact evaluation of a 31-gene expression profile test for management of melanoma patients. SKIN J Cutaneous Med. 2018;2:111–21. Dillon LD, Gadzia JE, Davidson RS, et al. Prospective, multicenter clinical impact evaluation of a 31-gene expression profile test for management of melanoma patients. SKIN J Cutaneous Med. 2018;2:111–21.
78.
go back to reference Scope A, Essat M, Pandor A, et al. Gene expression profiling and expanded immunohistochemistry tests to guide selection of chemotherapy regimens in breast cancer management: a systematic review. Int J Technol Assess Health Care. 2017;33:32–45.PubMed Scope A, Essat M, Pandor A, et al. Gene expression profiling and expanded immunohistochemistry tests to guide selection of chemotherapy regimens in breast cancer management: a systematic review. Int J Technol Assess Health Care. 2017;33:32–45.PubMed
79.
go back to reference Colomer R, Aranda-López I, Albanell J, et al. Biomarkers in breast cancer: a consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol. 2018;20:815–26.PubMed Colomer R, Aranda-López I, Albanell J, et al. Biomarkers in breast cancer: a consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol. 2018;20:815–26.PubMed
80.
go back to reference Sharma P, Barlow WE, Godwin AK, et al. Validation of the DNA damage immune response signature in patients with triple-negative breast cancer from the SWOG 9313c Trial. J Clin Oncol. 2019;37:3484–92.PubMedPubMedCentral Sharma P, Barlow WE, Godwin AK, et al. Validation of the DNA damage immune response signature in patients with triple-negative breast cancer from the SWOG 9313c Trial. J Clin Oncol. 2019;37:3484–92.PubMedPubMedCentral
81.
go back to reference Kohaar I, Petrovics G, Srivastava S. A rich array of prostate cancer molecular biomarkers: opportunities and challenges. Int J Mol Sci. 2019;20:1813.PubMedCentral Kohaar I, Petrovics G, Srivastava S. A rich array of prostate cancer molecular biomarkers: opportunities and challenges. Int J Mol Sci. 2019;20:1813.PubMedCentral
82.
go back to reference Kristiansen G. Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer. Mod Pathol. 2018;31:S143-155.PubMed Kristiansen G. Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer. Mod Pathol. 2018;31:S143-155.PubMed
83.
go back to reference Kretschmer A, Tilki D. Biomarkers in prostate cancer—current clinical utility and future perspectives. Crit Rev Oncol Hematol. 2017;120:180–93.PubMed Kretschmer A, Tilki D. Biomarkers in prostate cancer—current clinical utility and future perspectives. Crit Rev Oncol Hematol. 2017;120:180–93.PubMed
84.
go back to reference Chen K, Chen H, Yang F, et al. Validation of the eighth edition of the TNM staging system for lung cancer in 2043 surgically treated patients with non-small-cell lung cancer. Clin Lung Cancer. 2017;18:e457–66.PubMed Chen K, Chen H, Yang F, et al. Validation of the eighth edition of the TNM staging system for lung cancer in 2043 surgically treated patients with non-small-cell lung cancer. Clin Lung Cancer. 2017;18:e457–66.PubMed
85.
go back to reference Arroyo M, Larrosa R, Gómez-Maldonado J, Cobo MÁ, Claros MG, Bautista R. Expression-based, consistent biomarkers for prognosis and diagnosis in lung cancer. Clin Transl Oncol. 2020;22(10):1867–74.PubMed Arroyo M, Larrosa R, Gómez-Maldonado J, Cobo MÁ, Claros MG, Bautista R. Expression-based, consistent biomarkers for prognosis and diagnosis in lung cancer. Clin Transl Oncol. 2020;22(10):1867–74.PubMed
86.
go back to reference Yip L. Molecular markers for thyroid cancer diagnosis, prognosis, and targeted therapy. J Surg Oncol. 2015;111:43–50.PubMed Yip L. Molecular markers for thyroid cancer diagnosis, prognosis, and targeted therapy. J Surg Oncol. 2015;111:43–50.PubMed
87.
go back to reference Batista R, Vinagre N, Meireles S, et al. Biomarkers for bladder cancer diagnosis and surveillance: a comprehensive review. Diagnostics (Basel). 2020;10:39.PubMedCentral Batista R, Vinagre N, Meireles S, et al. Biomarkers for bladder cancer diagnosis and surveillance: a comprehensive review. Diagnostics (Basel). 2020;10:39.PubMedCentral
88.
go back to reference Arron ST, Blalock TW, Guenther JM, et al. Clinical considerations for integrating gene expression profiling into cutaneous squamous cell carcinoma management. J Drugs Dermatol. 2021;20:5s-s11.PubMed Arron ST, Blalock TW, Guenther JM, et al. Clinical considerations for integrating gene expression profiling into cutaneous squamous cell carcinoma management. J Drugs Dermatol. 2021;20:5s-s11.PubMed
89.
go back to reference Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol. 2018;78:237–47.PubMed Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol. 2018;78:237–47.PubMed
Metadata
Title
Current Methods and Caveats to Risk Factor Assessment in Cutaneous Squamous Cell Carcinoma (cSCC): A Narrative Review
Authors
Aaron S. Farberg
Alison L. Fitzgerald
Sherrif F. Ibrahim
Stan N. Tolkachjov
Teo Soleymani
Leah M. Douglas
Sarah J. Kurley
Sarah T. Arron
Publication date
01-02-2022
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 2/2022
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-021-00673-y

Other articles of this Issue 2/2022

Dermatology and Therapy 2/2022 Go to the issue